LAG3 and melanoma: Although the clinical benefit of LAG-3 inhibition with relatlimab and its establishment as a third immune checkpoint inhibitor has been clearly demonstrated, further investigation and studies are needed to understand the efficacy of relatlimab plus nivolumab in patient populations that are often excluded from clinical trials, such as patients with active or untreated brain metastases or with rare melanoma subtypes.